Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Saccharomyces boulardii as adjunctive treatment for depression
ChiCTR2600125737Phase 4Recruiting
- Sponsor
- First Affiliated Hospital of Kunming Medical University
- Start
- May 2026
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of saccharomyces boulardii in major depressive disorder (MDD) (2 arms), sponsored by First Affiliated Hospital of Kunming Medical University. Primary endpoints: Depression score at 3 months and Anxiety score at 3 months. Started May 2026; status: recruiting.
02
Drugs
saccharomyces boulardii
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2600125737.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600125737.